(Q40601455)

21 September 2017

title

Gonadotrophin-releasing hormone antagonists: will they replace the agonists? (English)

1 reference

21 September 2017

Ricardo E Felberbaum

1

1 reference

21 September 2017

Klaus Diedrich

series ordinal

2

1 reference

21 September 2017

publication date

1 January 2003

1 reference

Reproductive BioMedicine Online

21 September 2017

published in

1 reference

21 September 2017

volume

6

1 reference

21 September 2017

issue

1

1 reference

21 September 2017

page(s)

43-53

1 reference

Comparative trial of luteinizing hormone-releasing hormone analog/human menopausal gonadotropin and clomiphene citrate/human menopausal gonadotropin in an assisted conception program

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Addition of GnRH antagonist in cycles of poor responders undergoing IVF.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Comparison of different doses of gonadotropin-releasing hormone antagonist Cetrorelix during controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropin-releasing hormone antagonist Cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormone-releasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

GnRH antagonist in assisted reproduction: a Cochrane review

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Reflections on the cost-effectiveness of recombinant FSH in assisted reproduction. The clinician's perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The role of LHRH agonists and antagonists.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Cost-effectiveness modelling of recombinant FSH versus urinary FSH in assisted reproduction techniques in the UK

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

A pilot study involving minimal ovarian stimulation for in vitro fertilization: extending the "follicle-stimulating hormone window" combined with the gonadotropin-releasing hormone antagonist cetrorelix.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The role of gonadotropin-releasing hormone antagonists in in vitro fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The gonadotropin-releasing hormone antagonist (Nal-Glu) acutely blocks the luteinizing hormone surge but allows for resumption of folliculogenesis in normal women

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Time to revolutionize ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The pathophysiology of ovarian hyperstimulation syndrome--views and ideas

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Treatment with the gonadotrophin-releasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonists (Cetrorelix) in women with tubal infertility

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Hormone profiles under ovarian stimulation with human menopausal gonadotropin (hMG) and concomitant administration of the gonadotropin releasing hormone (GnRH)-antagonist Cetrorelix at different dosages.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Are we on the verge of a new era in ART?

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Prevention of premature luteinizing hormone and progesterone rise with a gonadotropin-releasing hormone antagonist, Nal-Glu, in controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The place of gonadotrophin-releasing hormone antagonists in reproductive medicine.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Extrapituitary Actions of Gonadotropin-Releasing Hormone*

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Gene expression of gonadotropin-releasing hormone, but not its receptor, in human endometrium and decidua

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Use of a single bolus of GnRH agonist triptorelin to trigger ovulation after GnRH antagonist ganirelix treatment in women undergoing ovarian stimulation for assisted reproduction, with special reference to the prevention of ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

High doses of gonadotrophin-releasing hormone antagonist in in-vitro fertilization cycles do not adversely affect the outcome of subsequent freeze-thaw cycles.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Plasma and follicular fluid concentrations of LHRH antagonist cetrorelix (Cetrotide) in controlled ovarian stimulation for IVF.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The single or dual administration of the gonadotropin-releasing hormone antagonist Cetrorelix in an in vitro fertilization-embryo transfer program.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Triggering of ovulation by a gonadotropin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The use of a GnRH antagonist (Cetrorelix) in a single dose protocol in IVF-embryo transfer: a dose finding study of 3 versus 2 mg

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin).

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Perinatal outcome of pregnancy after GnRH antagonist (ganirelix) treatment during ovarian stimulation for conventional IVF or ICSI: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Induction of ovulation for in-vitro fertilisation using buserelin and gonadotropins

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Quantitative gonadotropin-releasing hormone gene expression and immunohistochemical localization in human endometrium throughout the menstrual cycle

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Development and applications of luteinizing hormone-releasing hormone antagonists in the treatment of infertility: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Revival of the natural cycles in in-vitro fertilization with the use of a new gonadotrophin-releasing hormone antagonist (Cetrorelix): a pilot study with minimal stimulation

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Analysis of the cost effectiveness of recombinant versus urinary follicle-stimulating hormone in in vitro fertilization/intracytoplasmic sperm injection programs in the United States

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Impact of urinary FSH price: a cost-effectiveness analysis of recombinant and urinary FSH in assisted reproduction techniques in the USA

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

The use of gonadotrophin releasing hormone agonists for in vitro fertilization and other assisted procreation techniques: experience from three centres

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Reduced in-vitro fertilization of human oocytes from patients with raised basal luteinizing hormone levels during the follicular phase

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Possible direct effect of gonadotropin releasing hormone on human endometrium and decidua

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Reducing the Risk of Multiple Births by Transfer of Two Embryos after in Vitro Fertilization

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

Actions of gonadotropin-releasing hormone antagonists on steroidogenesis in human granulosa lutein cells

1 reference

https://api.crossref.org/works/10.1016%2FS1472-6483%2810%2962054-8

7 January 2021

10.1016/S1472-6483(10)62054-8

Identifiers

DOI

1 reference

21 September 2017

1 reference